Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN RAMON, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended...
-
Press release Ecully, February 29, 2024 – 6:00 p.m. Effective date of the Spineway reverse stock split Spineway announces the completion of the reverse stock split by exchanging 1 new share...
-
PALM BEACH GARDENS, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Great Elm Capital Corp. (“we,” “our,” the “Company” or “GECC,”) (NASDAQ: GECC), a business development company, today announced its...
-
2023 Fourth Quarter Revenue of $414.1 Million, up 10.5% year-over-yearQ4 Diluted EPS (GAAP) of $0.24, up 28.2% from $0.19 in Q4 of 2022Q4 Adjusted Diluted EPS (Non-GAAP) (2) of $0.35, up 11.3% from...
-
SANTIAGO, Chile, Feb. 28, 2024 (GLOBE NEWSWIRE) -- BANCO ITAÚ CHILE (SSE: ITAUCL) (the “Bank”) today announced that its Board of Directors has agreed, in its ordinary meeting held on this same date,...
-
ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
-
Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of...
-
Results for the Quarter and Fiscal Year Ended December 31, 2023 and Other Recent Highlights: Net investment income per share for the quarter was $0.46, compared to $0.43 for the quarter ended...
-
PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will conduct a reverse stock split of its...
-
FLORHAM PARK, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Celularity, Inc. (Nasdaq: CELU; CELUW) (“Celularity”), a biotechnology company developing allogeneic cell therapies and advanced biomaterial...